从生 officinale (生) 剥皮的再生保护性糖化物衍生物
Zhimin Song1, Hongbin Fang1, Xiaojuan Zhang1
1School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China.
Journal of agricultural and food chemistry
|October 9, 2023
概括
生皮化合物显示出治疗纤维化的潜力. 研究人员发现了新的葡萄糖类,并评估了它们对细胞外基质的影响,揭示了对纤维化有前途的治疗途径.
科学领域:
- 自然产品化学 自然产品化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 生 (Zingiber officinale) 是一种被广泛消费的香料和中国传统医药.
- 它传统上用于恶心,咳和感冒.
- 纤维化是一种病理过程,其特点是脏中细胞外基质的过度积累.
研究的目的:
- 从生皮中分离和描述新的化合物.
- 评估孤立化合物和已知的生醇的潜在纤维化活性.
主要方法:
- 使用色谱技术分离化合物.
- 使用HR-ESI-MS和广泛光谱方法 (UV,IR,1D-NMR,2D-NMR) 阐明结构.
- 使用NMR数据,量子力学NMR和TD-DFT ECD计算来确定立体化学配置.
- 在体外评估TGF-β1诱导的NRK-52E细胞中的纤维化活性.
主要成果:
- 从生皮中分离出18种新的糖化物 (1-18) 和6种已知的类似物 (19-24).
- 化合物9,10,15,22-24,6-银醇,8-银醇和10-银醇对细胞外矩阵积累表现出活性.
- 这些活性化合物表明对纤维化有潜在的治疗作用.
结论:
- 生皮是一种丰富的新型糖化物来源,具有潜在的药用特性.
- 特定的生糖化物和生醇表现出有前途的抗纤维性活性.
- 对这些化合物的进一步研究可能会导致纤维化治疗的新方法.
相关概念视频
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
468
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
468
01:05Proteoglycans
3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
445
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
445
01:23Dipeptidyl Peptidase 4 Inhibitors
196
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
196
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
195
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
195